Effect of mushroom polysaccharide injection on T-cell subset and soluble interleukin-2 receptor in peripheral blood in primary hepatoma patients

1998 ◽  
Vol 4 (4) ◽  
pp. 296-297
Author(s):  
Chen Weiqiang ◽  
Chen Yangshu
Keyword(s):  
T Cell ◽  
Peripheral Blood ◽  
Interleukin 2 ◽  
Cell Subset ◽  
Primary Hepatoma ◽  
T Cell Subset ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

scholarly journals Selective anergy of V beta 8+ T cells in human immunodeficiency virus-infected individuals.

1994 ◽  
Vol 179 (2) ◽  
pp. 413-424 ◽  
Author(s):  
G Dadaglio ◽  
S Garcia ◽  
L Montagnier ◽  
M L Gougeon
Keyword(s):  
Human Immunodeficiency Virus ◽  
T Cells ◽  
T Cell ◽  
Hiv Infection ◽  
Cd8 T Cells ◽  
Clinical Status ◽  
Interleukin 2 ◽  
Cell Subset ◽  
T Cell Subset ◽  
Immunodeficiency Virus

We have analyzed the V beta usage by CD4+ and CD8+ T cells from human immunodeficiency virus (HIV)-infected individuals in response to an in vitro stimulation with the superantigenic erythrogenic toxin A (ETA) of Streptococcus pyogenes. ETA amplifies specifically CD4+ and CD8+ T cells from control donors expressing the V beta 8 and the V beta 12 elements. When peripheral T cells from asymptomatic HIV-infected individuals were stimulated with ETA, there was a complete lack of activation of the V beta 8+ T cell subset, whereas the V beta 12+ T cell subset responded normally to the superantigen. This V beta-specific anergy, which was also observed in response to staphylococcal enterotoxin E (SEE), affected both CD4+ and CD8+ T cells and represented an intrinsic functional defect rather than a specific lack of response to bacterial superantigens since it was also observed after a stimulation with V beta 8 monoclonal antibodies. The V beta 8 anergic T cells did not express interleukin 2 receptors (IL-2Rs) and failed to proliferate in response to exogenous IL-2 or IL-4, suggesting that this anergy was not a reversible process, at least by the use of these cytokines. The unresponsiveness of the V beta 8 T cell subset is frequent since it was found in 56% of the patients studied, and comparison of the clinical status of responder vs. anergic patients indicated that the only known common factor between them was HIV infection. In addition, it is noteworthy that the anergy of the V beta 8 subset may be a very early phenomenon since it was found in a patient at Centers for Disease Control stage I of the disease. These data provide evidence that a dominant superantigen may be involved in the course of HIV infection and that the contribution of HIV has to be considered.

scholarly journals The CD8+ granzyme B+ T-cell subset in peripheral blood from healthy individuals contains activated and apoptosis-prone cells

Immunology ◽  
2001 ◽  
Vol 93 (3) ◽  
pp. 383-389 ◽  
Author(s):  
WEVER ◽  
VAN DER VLIET ◽  
SPAENY ◽  
WOLBINK ◽  
VAN DIEPEN ◽  
...  
Keyword(s):  
T Cell ◽  
Peripheral Blood ◽  
Granzyme B ◽  
Cell Subset ◽  
Healthy Individuals ◽  
T Cell Subset

Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma

1998 ◽  
Vol 38 (2) ◽  
pp. 207-220 ◽  
Author(s):  
Eric C. Vonderheid ◽  
Qian Zhang ◽  
Stuart R. Lessin ◽  
Marcia Polansky ◽  
J.Todd Abrams ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Interleukin 2 ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Interleukin 2 Receptor ◽  
Soluble Interleukin 2 Receptor

Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma

2015 ◽  
Vol 56 (9) ◽  
pp. 2592-2597 ◽  
Author(s):  
Souichi Shiratori ◽  
Mizuha Kosugi-Kanaya ◽  
Akio Shigematsu ◽  
Hajime Kobayashi ◽  
Satoshi Yamamoto ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Interleukin 2 ◽  
T Cell Lymphoma ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
Interleukin 2 Receptor ◽  
Poor Outcome ◽  
Soluble Interleukin 2 Receptor ◽  
High Level

scholarly journals Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects

Blood ◽  
1994 ◽  
Vol 83 (9) ◽  
pp. 2560-2569 ◽  
Author(s):  
M Sykes ◽  
MW Harty ◽  
GL Szot ◽  
DA Pearson
Keyword(s):  
T Cells ◽  
T Cell ◽  
Graft Versus Host Disease ◽  
Interleukin 2 ◽  
Cell Subset ◽  
Spleen Cells ◽  
Host Disease ◽  
Graft Versus Host ◽  
T Cell Subset ◽  
Graft Versus Leukemia

Abstract We have recently shown that a short course of high-dose interleukin-2 (IL-2) can markedly inhibit the graft-versus-host disease (GVHD)- promoting activity of donor CD4+ T cells. The difficulty in dissociating GVHD-promoting from graft-versus-leukemia (GVL) effects of alloreactive donor T cells currently prevents clinical bone marrow transplantation (BMT) from fulfilling its full potential. To test the capacity of IL-2 treatment to promote such a dissociation, we have developed a new murine transplantable acute myelogenous leukemia model using a class II major histocompatibility complex-positive BALB/c Moloney murine leukemia virus-induced promonocytic leukemia, 2B-4–2. BALB/c mice receiving 2.5 x 10(5) 2B-4–2 cells intravenously 1 week before irradiation and syngeneic BMT died from leukemia within 2 to 4 weeks after BMT. Administration of syngeneic spleen cells and/or a 2.5- day course of IL-2 treatment alone did not inhibit leukemic mortality. In contrast, administration of non-T-cell-depleted fully allogeneic B10 (H-2b) spleen cells and T-cell-depleted B10 marrow led to a significant delay in leukemic mortality in IL-2-treated mice. In these animals GVHD was inhibited by IL-2 treatment. GVL effects were mediated entirely by donor CD4+ and CD8+ T cells. Remarkably, IL-2 administration did not diminish the magnitude of the GVL effect of either T-cell subset. This was surprising, because CD4-mediated GVHD was inhibited in the same animals in which CD4-mediated GVL effects were not reduced by IL-2 treatment. These results suggest a novel mechanism by which GVHD and GVL effects of a single unprimed alloreactive T-cell subset can be dissociated; different CD4 activities promote GVHD and GVL effects, and the former, but not the latter activities are inhibited by treatment with IL-2.

scholarly journals Immunologic characterization of a helper T-cell lymphoma

Blood ◽  
1982 ◽  
Vol 59 (4) ◽  
pp. 702-708 ◽  
Author(s):  
M Gramatzki ◽  
MF Dolan ◽  
AS Fauci ◽  
JA Maples ◽  
GD Bonnard ◽  
...  
Keyword(s):  
T Cell ◽  
Peripheral Blood ◽  
Interleukin 2 ◽  
Cell Subset ◽  
Peripheral Blood Lymphocytes ◽  
Terminal Deoxynucleotidyl Transferase ◽  
Helper T Cell ◽  
Cell Surface Antigens ◽  
Polyclonal Hypergammaglobulinemia ◽  
Almost All

Abstract The lymphocytes of a patient with a T-cell non-Hodgkin's lymphoma with peripheral blood involvement and polyclonal hypergammaglobulinemia were characterized in terms of surface markers and immunologic functions. Using the fluorescence-activated cell sorter and employing various monoclonal antibodies against T-cell surface antigens, it was shown that almost all of the patient's peripheral blood lymphocytes were positive for OKT4 and 9.3, antibodies that recognize helper T-cell subset. The circulating lymphoma cells had typical characteristics for T cells; they formed spontaneous rosettes with sheep erythrocytes and stained with the pan-T-cell antibodies 9.6 and 10.2, but did not react with other anti-T-cell monoclonal reagents such as OKT3, UCHT-1, and 3A1. The cells appeared to be mature by the fact that they did not stain with OKT6, and terminal deoxynucleotidyl transferase was undetectable. Functionally, they were able to provide “help” for antibody production, and they could be stimulated to produce moderate amounts of interleukin-2, while unable to proliferate in response to mitogens. Morphologically, some of the lymphocytes showed a deeply cleaved nucleus.

Sign in / Sign up

Export Citation Format

Share Document